As filed with the Securities and Exchange Commission on August 14, 2018
Registration
No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
ACADIA PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
06-1376651
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification No.)
|
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
(858)
558-2871
(Address of Principal Executive Offices, Including Zip Code)
ACADIA Pharmaceuticals Inc.
2010 E
QUITY
I
NCENTIVE
P
LAN
(Full Title of the Plan)
Stephen R. Davis
President and Chief Executive Officer
ACADIA Pharmaceuticals Inc.
3611 Valley Centre Drive, Suite 300
San Diego, CA 92130
(Name
and Address of Agent for Service)
(858)
558-2871
(Telephone Number, Including Area Code, of Agent for Service)
Copies to:
L.
Kay Chandler, Esq.
Sean M. Clayton, Esq.
Cooley
LLP
4401 Eastgate Mall
San
Diego, CA 92121
(858)
550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See definitions of large accelerated filer, accelerated filer, smaller
reporting company and emerging growth company in Rule
12b-2
of the Securities Exchange Act of 1934:
|
|
|
|
|
|
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐